Status:
UNKNOWN
Early Diagnosis and Prognosis of Postoperative Sepsis by Presepsin and Syndecan-1
Lead Sponsor:
Alexandria University
Conditions:
Sepsis Following A Procedure
Diagnoses, Syndromes, and Conditions
Eligibility:
All Genders
18+ years
Brief Summary
The aim of the present work is to study: Persepsin (sCD-14) and Syndecan-1 as biomarkers following major surgeries for early diagnosis and prognosis of sepsis Primary aim: early diagnosis and prognosi...
Detailed Description
Millions of patients die around the world every year because of sepsis. 1%-2% of patients admitted to hospital and 25% of Intensive Care Units (ICU) patients suffer from sepsis. One of the most import...
Eligibility Criteria
Inclusion
- Adult patients aged ≥18 years, of either sex, after full recovery from anaesthesia and extubated, following scheduled major abdominal, abdomino-pelvic or vascular surgeries who develop an evident source of infection whether clinical, laboratory manifestation or radiological signs of infection and/or criteria of quick SOFA (qSOFA) after admission to ICU will be included in the study.
Exclusion
- Patients aged \<18 years old.
- Patients with terminal stage of malignancy of any type.
- Immune-compromised patients e.g., on immune-suppressive therapy, acquired immunodeficiency syndrome
- Patients with end-stage liver or renal disease.
- Patients with existing infection before surgery.
- Patients with emergency surgeries.
- Pregnancy.
- Chronic inflammatory disorders e.g., sarcoidosis
Key Trial Info
Start Date :
February 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04718623
Start Date
February 1 2021
End Date
April 1 2022
Last Update
January 22 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.